Source Count: 13 | Weighted Score: 33 | Source Confidence: [4/5] | Primary Tier: 1–2 | Last Updated: March 9, 2026
Keywords: HLA, MHC, major histocompatibility complex, immune diversity, balancing selection, antigen presentation, transplant rejection, autoimmune disease, pathogen-driven selection, HLA-B, HLA-A, HLA-DR, human leukocyte antigen, disassortative mating
Category Tags: genetics, immunology, evolution, health, population genetics
Cross-References: L_2_02 — Population Genetics Hardy-Weinberg · L_5_02 — Genetic Diseases Founder Populations · R_3_13 — Evolution Immune System · L_1_06 — Human Migration Synthesis

QUICK SUMMARY

The Human Leukocyte Antigen (HLA) system — the human version of the Major Histocompatibility Complex (MHC) found in all jawed vertebrates — is the most polymorphic gene region in the entire human genome. Located on chromosome 6p21.3, the HLA region spans ~4 megabases and encodes cell-surface glycoproteins that present peptide fragments to T cells, enabling the adaptive immune system to distinguish self from non-self. HLA Class I molecules (HLA-A, HLA-B, HLA-C) present intracellular peptides to CD8+ cytotoxic T cells; HLA Class II molecules (HLA-DR, HLA-DQ, HLA-DP) present extracellular peptides to CD4+ helper T cells. As of 2024, the IPD-IMGT/HLA Database records over 35,000 alleles across all HLA loci — an extraordinary level of diversity maintained by balancing selection (pathogen-driven frequency-dependent and heterozygote-advantage selection). The HLA system is central to transplant medicine (donor-recipient HLA matching determines organ transplant success), autoimmune disease (HLA alleles are the strongest genetic risk factors for type 1 diabetes, celiac disease, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis), and infectious disease susceptibility (specific HLA alleles influence HIV progression rate, hepatitis B clearance, malaria resistance). From an evolutionary perspective, HLA diversity represents one of the clearest examples of natural selection maintaining genetic variation in human populations — with some alleles shared across species lines (trans-species polymorphism; certain HLA lineages predate the human-chimpanzee divergence), demonstrating balancing selection operating over millions of years.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Scholarly Consensus)

1.1 Structure and Function

• HLA Class I (A, B, C): expressed on virtually all nucleated cells; present 8–10 amino acid peptides derived from intracellular proteins (including viral proteins) to CD8+ cytotoxic T lymphocytes; essential for cell-mediated immunity against intracellular pathogens
• HLA Class II (DR, DQ, DP): expressed primarily on antigen-presenting cells (dendritic cells, macrophages, B cells); present 13–25 amino acid peptides derived from extracellular proteins to CD4+ helper T cells; critical for activating adaptive immune responses
• The peptide-binding groove of HLA molecules (formed by the α1/α2 domains in Class I and α1/β1 domains in Class II) is the site of most polymorphism — different alleles bind different sets of peptides, meaning each HLA molecule "sees" a different slice of the pathogen proteome

1.2 Extreme Polymorphism

• HLA-B is the most polymorphic human gene, with over 8,000 alleles recorded (IPD-IMGT/HLA Database, 2024)
• Polymorphism is concentrated in the peptide-binding groove residues — the positions that directly contact antigenic peptides — consistent with selection for diversity in pathogen recognition
• Heterozygote advantage: individuals heterozygous at HLA loci can present a broader range of pathogen-derived peptides than homozygotes, conferring superior immune response; supported by studies showing HLA-heterozygous individuals clear hepatitis B more effectively (Thursz et al., 1997, Nature Genetics) and have reduced HIV viral loads (Carrington et al., 1999, Science)

1.3 Disease Associations

• Ankylosing spondylitis: HLA-B_2_11 allele confers ~100-fold increased risk (one of the strongest genetic disease associations known)
• Type 1 diabetes: HLA-DR3 and HLA-DR4 haplotypes account for ~40–50% of genetic risk
• Celiac disease: HLA-DQ2 (present in ~95% of patients) and HLA-DQ8 are necessary (though not sufficient) for disease development
• HIV/AIDS: HLA-B57:01 and HLA-B27:05 are associated with slow progression to AIDS ("elite controller" status); HLA-B*35 is associated with rapid progression

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Trans-Species Polymorphism

• Some HLA allele lineages are older than the human species itself — shared polymorphisms between humans and chimpanzees (and in some cases other Old World primates) indicate that balancing selection has maintained specific allelic lineages for >5 million years (Klein et al., 1998, Annual Review of Immunology)
• This trans-species polymorphism is one of the strongest pieces of evidence for long-term balancing selection in the vertebrate genome

2.2 Pathogen-Driven Selection and Population Variation

• HLA allele frequencies vary significantly between populations, and this variation correlates with local pathogen diversity — populations in regions with high pathogen burden (tropical regions) tend to have greater HLA diversity (Prugnolle et al., 2005, Current Biology)
• This pattern is consistent with frequency-dependent selection: rare HLA alleles have an advantage because pathogens are less likely to have evolved evasion strategies against uncommon host alleles, maintaining diversity in the population

2.3 MHC-Based Mate Choice

• Studies in mice (Yamazaki et al., 1976) and fish (stickleback, Reusch et al., 2001) show MHC-disassortative mating preference — individuals preferring mates with different MHC alleles, potentially mediated through olfactory cues
• Human studies are more equivocal: the "sweaty T-shirt experiment" (Wedekind et al., 1995, Proceedings of the Royal Society B) suggested women preferred the body odor of men with dissimilar HLA alleles (when not using hormonal contraceptives), but replication studies have yielded mixed results

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 HLA and Olfactory Mate Selection in Humans

• Whether HLA-based mate choice operates meaningfully in modern human populations remains unproven; studies have produced conflicting results and face confounds from strong cultural influences on mate selection
• If confirmed, the mechanism would likely involve olfactory detection of HLA-dependent peptide-microbiome interactions affecting body odor

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 HLA Type as Racial Classifier

• DEBUNKED Attempts to use HLA types as markers of "racial purity" or fixed racial categories misrepresent the data; HLA allele frequencies differ between populations as gradients (clines), not as discrete racial boundaries, and most alleles are shared across populations at varying frequencies

Counter-Arguments

• HLA diversity demonstrates that human genetic variation is a continuum shaped by local pathogen environments and migration history, not by discrete racial categories

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Robinson, J. et al | 2020 | "IPD-IMGT/HLA Database" | Nucleic Acids Research | ∅ | ∅ | 48.D1 : D783 D788 | ∅ | doi:10.1093/nar/gku1161 | ∅ | ∅ | ∅
2. Klein, J. et al | 1998 | "The Molecular Descent of the Major Histocompatibility Complex" | Annual Review of Immunology | ∅ | 16::359–393 | ∅ | ∅ | doi:10.1146/annurev.immunol.11.1.269 | ∅ | ∅ | ∅
3. Carrington, M. et al | 1999 | "HLA and HIV-1: Heterozygote Advantage and B35-Cw04 Disadvantage" | Science | ∅ | 283.5408::1748–1752 | ∅ | ∅ | doi:10.1126/science.283.5408.1748 | ∅ | ∅ | ∅
4. Thursz, M.R. et al | 1997 | "Heterozygote Advantage for HLA Class-II Type in Hepatitis B Virus Infection" | Nature Genetics | ∅ | 17::11–12 | ∅ | ∅ | doi:10.1038/ng0997-11 | ∅ | ∅ | ∅
5. Prugnolle, F. et al | 2005 | "Pathogen-Driven Selection and Worldwide HLA Class I Diversity" | Current Biology | ∅ | 15.11::1022–1027 | ∅ | ∅ | doi:10.1016/j.cub.2005.04.050 | ∅ | ∅ | ∅
6. Wedekind, C. et al | 1995 | "MHC-Dependent Mate Preferences in Humans" | Proceedings of the Royal Society B | ∅ | 260.1359::245–249 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Fernando, M.M.A. et al. e169 | 2008 | "Defining the Role of the MHC in Autoimmunity: A Review" | PLoS Medicine | ∅ | 5.8:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Matzaraki, V. et al | 2017 | "The MHC Locus and Genetic Susceptibility to Autoimmune and Infectious Diseases" | Genome Biology | ∅ | 18::76 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Sommer, S | 2005 | "The Importance of Immune Gene Variability (MHC) in Evolutionary Ecology and Conservation" | Frontiers in Zoology | ∅ | 2::16 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Penn, D.J.; Potts, W.K | 1999 | "The Evolution of Mating Preferences and Major Histocompatibility Complex Genes" | American Naturalist | ∅ | 153.2::145–164 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Trowsdale, J.; Knight, J.C | 2013 | "Major Histocompatibility Complex Genomics and Human Disease" | Annual Review of Genomics and Human Genetics | ∅ | 14::301–323 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Brown, J.H. et al | 1993 | "Three-Dimensional Structure of the Human Class II Histocompatibility Antigen HLA-DR1" | Nature | ∅ | 364::33–39 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. de Bakker, P.I.W. et al | 2006 | "A High-Resolution HLA and SNP Haplotype Map for Disease Association Studies in the Extended Human MHC" | Nature Genetics | ∅ | 38::1166–1172 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Last Updated: March 9, 2026

<table border="1" cellpadding="12" cellspacing="0" style="border-collapse: collapse; border: 2px solid #888; margin-top: 2em; background: #fafafa;">

<tr><td>

⚠️ AI-Assisted Research Disclaimer

This document was generated and structured with the assistance of AI tools.

While every effort is made to ensure accuracy, AI-assisted content may

contain errors, misattributions, or unintended inaccuracies. **Always

verify claims, dates, and sources independently** before citing or relying

on any information presented here.

• Sources may contain errors. Bibliography entries and cross-references

are checked by automated systems, but mistakes can occur. If something

looks wrong, it may be.

• Speculative and unverified claims are clearly labeled. This project

uses a four-tier evidence system:

• Tier 1 — Verified: Peer-reviewed, established scientific consensus.
• Tier 2 — Credible: Academically supported, debated but grounded.
• Tier 3 — Speculative: Plausible but unverified by mainstream science.
• Tier 4 — Dubious: No credible support or contradicted by evidence.
• This project maps multiple perspectives — not a single truth. Mainstream,

alternative, and skeptical viewpoints are presented side by side for

critical comparison, not endorsement. Inclusion does not imply agreement.

• We are actively improving. Source verification, factuality scoring,

and bibliography enrichment are ongoing. Each revision adds stronger

citations, corrects identified errors, and expands coverage.

📖 For full details on our verification methodology, scoring systems, and

quality metrics, see: Fact-Checking & Verification Systems

Think Openly. Check the sources. Draw your own conclusions.

</td></tr>

</table>